LTR Pharma Limited (AU:LTP) has released an update.
LTR Pharma Limited reports a transformative year with their innovative erectile dysfunction nasal spray, SPONTAN, showing rapid absorption and faster action in clinical studies, alongside successful IPO and ASX listing. The company secured a $10.5 million placement and key partnerships for SPONTAN’s commercialization, while maintaining a healthy cash balance of $3.10 million. These achievements demonstrate LTR Pharma’s commitment to meeting investor expectations and advancing their product to market.
For further insights into AU:LTP stock, check out TipRanks’ Stock Analysis page.
